Source: International Congress 2019 – Physiologic assessment of airway diseases
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Hagberg (Gothenburg, Sweden), J. Betts (Gothenburg, Sweden), C. Kristensson (Gothenburg, Sweden), J. Mo (Gothenburg, Sweden), S. Asimus (Gothenburg, Sweden), M. Sadiq (Gothenburg, Sweden), T. Koernicke (Berlin, Germany), R. Fuhr (Berlin, Germany), W. Brailsford (Gothenburg, Sweden), C. Keen (Gothenburg, Sweden), J. Mäenpää (Gothenburg, Sweden). Reducing the variability of DLCO measurements in clinical trials. 2650

Member's Comments

No comment yet.

Related content which might interest you: DLco simulations for qualification of DLco devices globally for inhaled levodopa clinical trials. Source: International Congress 2019 – Quality, performance and interpretation of lung function testing Year: 2019 COPDGene intra-subject variability of DLco measurements using an ultrasound-based instrument Source: International Congress 2015 – Monitoring airway diseases with lung function tests Year: 2015 Measuring bronchodilation in COPD clinical trials Source: Eur Respir J 2004; 24: Suppl. 48, 122s Year: 2004 Correlations of ventilation heterogeneity and spirometry in asthma; initial experience with hyperpolarised gas MRI in a clinical setting. Source: International Congress 2019 – Imaging in respiratory disease: novel technologies in 2019 Year: 2019 Reproducibility of measurements of inspiratory capacity, dyspnea intensity and exercise endurance in multicentre trials in COPD Source: Eur Respir J 2004; 24: Suppl. 48, 323s Year: 2004 Duration and frequency of spirometry needed to accurately reflect longitudinal change of FEV1 in COPD Source: Virtual Congress 2021 – Lung function testing in the management of obstructive diseases Year: 2021 Prevalence of altering selected spirometry maneuvers in asthma clinical trials. Source: Virtual Congress 2021 – Future advances in respiratory physiology Year: 2021 Do changes in spirometric indices and FeNO predict asthma outcomes in children? An individual patient data analysis using results from seven FeNO trials Source: International Congress 2018 – Primary ciliary dyskinesia and lung function tests in respiratory morbidities Year: 2018 Quality control of DL,CO instruments in global clinical trials Source: Eur Respir J 2009; 33: 828-834 Year: 2009 When is FEV1 loss excessive? – an investigation of the relationship between year-to-year and long-term spirometry changes Source: Annual Congress 2004 - Longitudinal studies and determinants of lung function and COPD Year: 2004 Relationship between change in trough FEV1 and COPD patient outcomes: Pooled analysis of 23 clinical trials in patients with COPD Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Pooled clinical trial analysis of the rate of decline in FEV1 according to perceived dyspnea and health status Source: Annual Congress 2008 - COPD: from bench to bedside Year: 2008 Clinical relevance of constant power exercise duration changes in COPD Source: Annual Congress 2009 - Influence of interventions and comorbidity on exercise performance Year: 2009 Pattern of diffusion disturbance related to clinical diagnosis: the KCO has no additional diagnostic value next to the DLCO Source: Eur Respir J 2005; 26: Suppl. 49, 523s Year: 2005 The clinical value of bodybox measurements Source: International Congress 2015 – CC5 Interpretation of pulmonary function testing Year: 2015 DLCO biological controls in clinical practice. Source: International Congress 2019 – Quality, performance and interpretation of lung function testing Year: 2019 The ratio of inspiratory ΣRrs to expiratory ΣRrs measured by forced oscillation technique correlates with the parameters reflecting narrowing of small airway measured by spirometry in patients with mild to moderate COPD Source: Annual Congress 2013 –New issues in lung function testing Year: 2013 FEV6: a useful outcome measure of lung function in COPD as assessed in a large clinical study with roflumilast Source: Eur Respir J 2004; 24: Suppl. 48, 342s Year: 2004 DLCO: adjust for lung volume, standardised reporting and interpretation Source: Eur Respir J, 50 (2) 1700940; 10.1183/13993003.00940-2017 Year: 2017 DLCO: adjust for lung volume, standardised reporting and interpretation Source: Eur Respir J, 50 (2) 1701144; 10.1183/13993003.01144-2017 Year: 2017